Want to see BMRA full AI Analyst Report?
Top Page
Biomerica
(NASDAQ:BMRA)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.50
▲(19.05% Upside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by weak financial performance—low gross margins, large ongoing losses, and persistent cash burn—plus a weakening capital structure trend. Technicals are supportive in the near term (above key moving averages with positive MACD) but look overextended (high RSI/Stoch). Valuation is constrained by negative earnings, while the recent private placement modestly improves liquidity but underscores continued dependence on external funding.
Positive Factors
Recurring diagnostic consumables
Sales of test kits, assays, and consumables can generate repeat demand as customers continue testing patients. This recurring-use model gives Biomerica a foundation for revenue continuity and provides an avenue for growth if adoption expands across laboratories, healthcare providers, and distributors.
Negative Factors
Revenue contraction and volatility
The substantial decline from 2022 revenue indicates that Biomerica has not yet established durable commercial scale. Volatile and smaller sales reduce operating leverage, make fixed costs harder to absorb, and leave future financial performance highly dependent on renewed product demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring diagnostic consumables
Sales of test kits, assays, and consumables can generate repeat demand as customers continue testing patients. This recurring-use model gives Biomerica a foundation for revenue continuity and provides an avenue for growth if adoption expands across laboratories, healthcare providers, and distributors.
Read all positive factors
Biomerica (BMRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.28M
Dividend YieldN/A
Average Volume (3M)142.14K
Price to Earnings (P/E)―
Beta (1Y)2.04
Revenue Growth-16.17%
EPS Growth41.61%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.26
Shares Outstanding4,598,968
10 Day Avg. Volume34,665
30 Day Avg. Volume142,144
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.62
Price to Sales (P/S)1.54
P/FCF Ratio-2.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biomerica Business Overview & Revenue Model
Company Description
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases...
How the Company Makes Money
Biomerica makes money primarily by selling its diagnostic products and related consumables to customers such as clinical laboratories, hospitals/clinics, and distributors. Revenue is generally generated from (1) product sales of test kits and assa...
Biomerica Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.45M | 5.31M | 5.42M | 5.34M | 18.87M |
| Gross Profit | 362.00K | 498.00K | 611.00K | 446.00K | 2.98M |
| EBITDA | -4.90M | -4.57M | -5.56M | -6.74M | -3.94M |
| Net Income | -3.77M | -4.97M | -5.98M | -7.14M | -4.53M |
Balance Sheet | |||||
| Total Assets | 6.76M | 5.95M | 9.25M | 14.45M | 11.37M |
| Cash, Cash Equivalents and Short-Term Investments | 1.31M | 2.40M | 4.17M | 9.72M | 5.92M |
| Total Debt | 2.38M | 458.00K | 785.00K | 1.08M | 1.38M |
| Total Liabilities | 4.13M | 1.84M | 2.66M | 2.73M | 3.05M |
| Stockholders Equity | 2.63M | 4.11M | 6.59M | 11.72M | 8.32M |
Cash Flow | |||||
| Free Cash Flow | -3.42M | -3.88M | -5.48M | -5.55M | -650.87K |
| Operating Cash Flow | -3.42M | -3.84M | -5.36M | -5.47M | -480.53K |
| Investing Cash Flow | -1.00K | -37.00K | -115.00K | -78.00K | -170.34K |
| Financing Cash Flow | 2.33M | 2.11M | -81.00K | 9.39M | 2.39M |
Biomerica Technical Analysis
Neutral
2.10
Price Trends
1.97
Positive
1.97
Positive
2.13
Positive
Market Momentum
0.08
Positive
45.41
Neutral
6.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRA, the sentiment is Neutral. The current price of 2.1 is below the 20-day moving average (MA) of 2.37, above the 50-day MA of 1.97, and below the 200-day MA of 2.13, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 45.41 is Neutral, neither overbought nor oversold. The STOCH value of 6.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BMRA.
Biomerica Risk Analysis
Biomerica disclosed 33 risk factors in its most recent earnings report. Biomerica reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biomerica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $18.67M | -1.34 | -816.25% | ― | -27.70% | 61.44% | |
48 Neutral | $10.28M | -1.70 | -97.19% | ― | -16.17% | 41.61% | |
45 Neutral | $21.59M | -0.18 | -33.51% | ― | -89.02% | -107.75% | |
40 Underperform | $6.00 | >-0.01 | -360.33% | ― | -8.54% | 40.91% | |
40 Underperform | $7.68M | -0.08 | -267.73% | ― | ― | 64.78% |
* Healthcare Sector Average
BMRA
Biomerica
2.14
-0.66
-23.50%
SSKN
Strata Skin Sciences
0.09
-2.02
-95.73%
PAVM
PAVmed
2.87
-10.19
-78.02%
HSCS
Heart Test Laboratories, Inc.
4.30
0.60
16.22%
AMIX
Autonomix Medical, Inc.
3.78
-20.16
-84.21%
Biomerica Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Biomerica Completes Private Placement of Equity Securities
Positive
Aug 26, 2026
On August 20, 2026, Biomerica entered into a securities purchase agreement with institutional and individual investors, including B. Riley Principal Capital and certain directors and executives, to sell 1,393,705 common shares at $1.60 each, raisi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.